https://bizups.info/legal/616/fahttps://bizups.info/news/3222/Lumira Ventures is proud to introduce the newest cohort joining our Venture Innovation Program (VIP) for the 2024-2025 term. The VIP program offers Ph.D., MBA, and MD students across Canada a unique opportunity to gain hands-on experience in life sciences venture capital and startups, nurturing the next generation of leaders, and contributing to the future […] The post Building the Future: Meet the 2024 – 2025 Lumira Venture Innovation Program (VIP) Fellows appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3127/Congruence Therapeutics today announced that it has entered into a research collaboration agreement with Ono Pharmaceutical Co., Ltd. (Ono) to discover novel drug candidates leveraging Congruence's proprietary drug discovery platform, Revenir™. Congruence will apply its technology and expertise toward multiple cancer protein targets. Once the discovery effort advances to a prespecified stage, Ono has the option […] The post Congruence and Ono Announce Multi-Target Research Collaboration to Generate Small Molecule Correctors for the Treatment of Cancer appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3126/COUR Pharmaceuticals, a clinical-stage biotechnology company developing first- in-class, disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, today announced a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, for the development and commercialization of COUR’s proprietary tolerogenic nanoparticle treatments for an autoimmune disease. “Genentech has a long history of […] The post COUR Pharmaceuticals Enters Collaboration and Licensing Agreement with Genentech to Develop and Commercialize Tolerogenic Therapy for the Treatment of an Autoimmune Disease appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3124/KisoJi Biotechnology Inc., a company focused on the discovery and development of transformative antibody therapeutics, announces that it has raised $41 million in equity, including the conversion of previously funded convertible debentures. These funds will be used to advance its lead asset, KJ-103, the first potent naked antibody against TROP2, into the clinic to treat […] The post KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic and Deploy AI Tools Into Key Pipeline Indications appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3096/Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, today announced the acquisition of a portfolio of novel nucleoside analogs from PrimeFour Therapeutics, Inc., a biotechnology company focused on cancer chemotherapeutic agents. The portfolio of novel nucleosides consists of a chemically diverse library […] The post Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3081/AmacaThera today announced results from its Phase 1 clinical trial of AMT-143, an innovative, non-opioid anesthetic, formulated with the company's patented AmacaGel™ platform, demonstrating sustained anesthetic release out to 14 days. AMT-143 is intended to deliver extended, localized pain relief without the need for opioids, significantly reducing the risks associated with opioid addiction and side […] The post AmacaThera Exceeds Expectations with Phase 1 Results of First-in-Human Study with AMT-143, Paving the Way for a Novel Approach to Post-Operative Pain Relief appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3080/Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce the appointment of Amy Sehnert, MD, as Chief Medical Officer (CMO). Dr. Sehnert will lead the clinical development and strategy for Thryv Therapeutics’ expanding cardiometabolic product portfolio targeting serum glucocorticoid inducible kinase 1 (SGK1) – a kinase implicated […] The post Thryv Therapeutics Appoints Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical Officer appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3068/HistoSonics, the developer and manufacturer of the Edison® Histotripsy System, announced today the first patients were enrolled in their novel prospective master protocol study, called BOOMBOX, designed to evaluate the real-world use of histotripsy for treatment of liver tumors. BOOMBOX is a comprehensive, post-market master study that will provide important data for up to 5,000 […] The post HistoSonics® Enrolls First Patients in Company’s Novel BOOMBOX Master Study appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3067/Nocion Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel small molecule charged sodium channel blockers called “nocions”, that selectively silence actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain, today announced that the first patient has been dosed in the Phase 2b ASPIRE clinical trial of taplucainium for the […] The post Nocion Therapeutics Doses First Patient in ASPIRE Phase 2b Chronic Cough Study appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3038/Thryv Therapeutics Inc., a biotechnology company pioneering treatments for genetic and cardiometabolic conditions, including congenital Long QT Syndrome, heart failure, and atrial fibrillation, has completed phase 1 dosing of its second SGK1 inhibitor. This study was a first-in-human, randomized, double- blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and food […] The post Thryv Therapeutics Completes Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025 appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3002/COUR Pharmaceuticals, a clinical-stage biotechnology company developing first- in-class, disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, today announced positive 120-day data from its Phase 2a study evaluating CNP-104 as a potential treatment for patients with Primary Biliary Cholangitis (PBC), a chronic liver disease that is estimated to affect approximately 130,000 individuals in the […] The post COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3001/Thryv Therapeutics Inc., a clinical-stage biotechnology company, received positive top-line results from the Wave I Part 2 proof-of-concept clinical study evaluating LQT-1213 for the treatment of congenital Long QT Syndrome (cLQTS) Types 2 and 3. LQT-1213, a potent and selective serum glucocorticoid inducible kinase 1 (SGK1) inhibitor, demonstrated clinically meaningful and statistically significant reductions in […] The post Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/3000/Thryv Therapeutics Inc., a clinical stage biotech company dedicated to developing treatments for rare and life-threatening cardiovascular indications, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to LQT-1213 for the treatment of Long QT Syndrome (LQTS). LQT-1213 is a novel, first-in-class SGK1 inhibitor specifically designed to treat […] The post Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/2999/COUR Pharmaceuticals, a clinical-stage biotechnology company developing first- in-class, disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, today announced that as part of a leadership succession plan, John J. Puisis will transition his responsibilities as President and Chief Executive Officer of COUR to the Company’s Chief Operating Officer, Dannielle Appelhans, effective September 1, 2024. […] The post COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada. https://bizups.info/news/2998/COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class, disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, today announced the appointment of Tim Walbert, an industry veteran with more than 30 years of leadership experience in biotech, to its Board of Directors, effective immediately. Mr. Walbert joins COUR after a […] The post COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors appeared first on Lumira Ventures | Venture Capital Life Sciences | Canada.